Summit Therapeutics (SMMT) Operating Expenses (2019 - 2026)

Summit Therapeutics has reported Operating Expenses for 8 years, with the latest figure at $195.2 million in Q1 2026.

• For the quarter ending Q1 2026, Operating Expenses rose 192.01% year-over-year to $195.2 million; the trailing twelve-month figure through Mar 2026 stood at $1.2 billion (up 388.22% YoY), and the FY2025 full-year result was $1.1 billion, up 384.26% from the prior year.
• Operating Expenses for Q1 2026 stood at $195.2 million, down from $224.9 million in the prior quarter.
• The five-year high for Operating Expenses was $568.4 million in Q2 2025, with the low at $15.8 million in Q2 2023.
• Historically, Operating Expenses has averaged $130.1 million across 5 years, with a median of $58.4 million in 2024.
• Annual changes were most pronounced in 2023 — Operating Expenses jumped 1875.89% — and 2024, when it tumbled 92.12%.
• Summit Therapeutics' Operating Expenses stood at $21.4 million in 2022, then soared by 65.12% to $35.4 million in 2023, then soared by 85.41% to $65.6 million in 2024, then soared by 242.8% to $224.9 million in 2025, then decreased by 13.21% to $195.2 million in 2026.
• The last three Operating Expenses figures came in at $195.2 million (Q1 2026), $224.9 million (Q4 2025), and $234.2 million (Q3 2025), per Business Quant data.